Stock listing
OTC:TRVN Trevena, Inc. Stock
Follow Trevena, Inc. into a list and get an email when it puts out news.
Share price · OTC:TRVN
$0.0005 USD 0.0000 (0.0%)
Close on Nov 16, 2026
- Day range
- $0.0005 – $0.0005 USDNov 16, 2026
- Market cap
- $432 USDAt the close on Nov 16, 2026 · price × 863,788 shares outstanding
- Traded on an average day
- $0 USDMedian day 0 shares · 18 days with no trades · last 3 months, Oct 16, 2026 – Nov 16, 2026

Daily closes
Last 3 months, Oct 16, 2026 – Nov 16, 2026 · OTC:TRVN · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.0005 | 0.0000 | 0.0% | $0.0005 | $0.0005 | $0.0005 | 0 | |
| $0.0005 | +0.0001 | +25.0% | $0.0005 | $0.0005 | $0.0005 | 977 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 0 | |
| $0.0004 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 0 | |
| $0.0004 | -0.0107 | -96.4% | $0.0004 | $0.0004 | $0.0004 | 117 | |
| $0.0111 | 0.0000 | 0.0% | $0.0111 | $0.0111 | $0.0111 | 0 | |
| $0.0111 | 0.0000 | 0.0% | $0.0111 | $0.0111 | $0.0111 | 0 | |
| $0.0111 | 0.0000 | 0.0% | $0.0111 | $0.0111 | $0.0111 | 0 | |
| $0.0111 | 0.0000 | 0.0% | $0.0111 | $0.0111 | $0.0111 | 0 | |
| $0.0111 | 0.0000 | 0.0% | $0.0111 | $0.0111 | $0.0111 | 0 | |
| $0.0111 | 0.0000 | 0.0% | $0.0111 | $0.0111 | $0.0111 | 0 | |
| $0.0111 | 0.0000 | 0.0% | $0.0111 | $0.0111 | $0.0111 | 0 | |
| $0.0111 | 0.0000 | 0.0% | $0.0111 | $0.0111 | $0.0111 | 0 | |
| $0.0111 | 0.0000 | 0.0% | $0.0111 | $0.0111 | $0.0111 | 0 | |
| $0.0111 | 0.0000 | 0.0% | $0.0111 | $0.0111 | $0.0111 | 0 | |
| $0.0111 | +0.0106 | +2120.0% | $0.0111 | $0.0111 | $0.0111 | 254 | |
| $0.0005 | 0.0000 | 0.0% | $0.0005 | $0.0005 | $0.0005 | 0 | |
| $0.0005 | 0.0000 | 0.0% | $0.0005 | $0.0005 | $0.0005 | 0 | |
| $0.0005 | 0.0000 | 0.0% | $0.0005 | $0.0005 | $0.0005 | 0 | |
| $0.0005 | 0.0000 | 0.0% | $0.0005 | $0.0005 | $0.0005 | 0 | |
| $0.0005 | 0.0000 | 0.0% | $0.0005 | $0.0005 | $0.0005 | 0 | |
| $0.0005 | — | — | $0.0004 | $0.0005 | $0.0004 | 4,129 |
Splits
2 splits since 2022 · OTC:TRVN · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-25 | Consolidation | |
| 1-for-25 | Consolidation |
- Ticker
- OTC:TRVN
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
Trevena, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- Calls
- 9 calls with a replay · 9 with a transcript · latest Nov 14, 2023
- Decks
- 25 decks · latest March 2025
Valuation
price Nov 16, 2026
- Enterprise value
- No statements on 6ix yet
- P/E
- No statements on 6ix yet
- EV/sales
- No statements on 6ix yet
- EV/EBITDA
- No statements on 6ix yet
- Price/book
- No statements on 6ix yet
- Gross margin
- No statements on 6ix yet
- Operating margin
- No statements on 6ix yet
- Net margin
- No statements on 6ix yet
- Debt to equity
- No statements on 6ix yet
- Beta vs S&P 500
- 0.23
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Trevena, Inc. · OTC:TRVN | US$432 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 0.23 |
| Chimeric Therapeutics Limited · ASX:CHM | US$292,816 | −US$220,193 | n/a | −0.1× | n/a | 0.2× | −262.8% | 2.5× | n/a |
| CERo Therapeutics Holdings, Inc. · OTC:CERO | US$265,035 | −US$190,890 | n/a | n/a | n/a | n/a | n/a | n/a | 1.47 |
| CDT Equity Inc. · NASDAQ:CDT | US$234,109 | −US$1.49M | n/a | n/a | n/a | 0.0× | n/a | 0.0× | 1.14 |
| GlucoTrack, Inc. · NASDAQ:GCTK | US$217,049 | −US$887,951 | n/a | n/a | n/a | n/a | n/a | n/a | 1.73 |
| Regen BioPharma, Inc. · OTC:RGBP | US$167,528 | US$167,289 | n/a | 0.7× | n/a | n/a | −501.4% | n/a | 1.20 |
| CNBX Pharmaceuticals Inc. · OTC:CNBX | US$160,577 | US$151,090 | n/a | n/a | n/a | n/a | n/a | n/a | 1.78 |
| Fifty 1 Labs Inc. · OTC:FITY | US$118,532 | US$282,021 | n/a | 6,000× | n/a | n/a | n/a | n/a | -1.17 |
| GB Sciences, Inc. · OTC:GBLX | US$81,414 | US$2.07M | n/a | n/a | n/a | n/a | n/a | n/a | -0.46 |
| Lyra Therapeutics, Inc. · OTC:LYRA | US$53,246 | US$14.42M | n/a | 36.2× | n/a | n/a | n/a | n/a | 0.67 |
| ZyVersa Therapeutics, Inc. · OTC:ZVSA | US$810 | US$1.20B | n/a | n/a | n/a | n/a | n/a | n/a | -0.56 |
| Median of the others | US$164,053 | US$159,190 | 18.5× | 0.1× | −382.1% | 1.3× | 1.14 |
Team and board
Officers
| Officer | Role |
|---|---|
| Carrie L. Bourdow | President and Chief Executive Officer |
| Scott Applebaum | Corporate Secretary |
| Robert Yoder | Senior Vice President and Chief Business Officer |
| Michael R. Dougherty | Executive Chairman |
Board
| Director | Role |
|---|---|
| Leon O. Moulder | Chairman of the Board |
| Michael R. Dougherty | Executive Chairman |
| Anne M. Phillips | Member of Nominating and Corporate Governance Committee |
| Barbara Yanni | Chair of Compensation Committee |
| Carrie L. Bourdow | President and Chief Executive Officer |
| Jake R. Nunn | Member of the Nominating and Corporate Governance Committee |
| Julie H. McHugh | Chair of the Nominating and Corporate Governance Committee |
| Maxine Gowen | Director |
| Scott Braunstein | Operating Partner at Aisling Capital Management LP |
Events
Calls
| Call | When | Status |
|---|---|---|
| Trevena (OTC:TRVN) Q3 2023 Earnings Call | Tue, Nov 14, 2023 · 8:00 AM ET | Replay |
| Trevena (OTC:TRVN) Q1 2023 Earnings Call | Mon, May 15, 2023 · 8:00 AM ET | Replay |
| Trevena (OTC:TRVN) Q4 2022 Earnings Call | Thu, Mar 30, 2023 · 8:00 AM ET | Replay |
| Trevena (OTC:TRVN) Q3 2022 Earnings Call | Wed, Nov 09, 2022 · 8:00 AM ET | Replay |
| Trevena (OTC:TRVN) Q2 2022 Earnings Call | Thu, Aug 11, 2022 · 8:00 AM ET | Replay |
| Trevena (OTC:TRVN) Q1 2022 Earnings Call | Wed, May 11, 2022 · 8:00 AM ET | Replay |
| Trevena (OTC:TRVN) Q4 2021 Earnings Call | Thu, Mar 31, 2022 · 8:00 AM ET | Replay |
| Trevena (OTC:TRVN) Q3 2021 Earnings Call | Mon, Nov 15, 2021 · 8:00 AM ET | Replay |
| Trevena (OTC:TRVN) Q4 2020 Earnings Call | Tue, Mar 09, 2021 · 8:00 AM ET | Replay |
Results days
| Quarter | Results |
|---|---|
| Q3 2024 | Nov 7, 2024 · Before open |
| Q2 2024 | Aug 8, 2024 · Before open |
| Q1 2024 | May 15, 2024 · Before open |
| Q4 2023 | Mar 28, 2024 · Before open |
| Q3 2023 | Nov 14, 2023 · Before open |
| Q2 2023 | Aug 14, 2023 · Before open |
| Q1 2023 | May 15, 2023 · Before open |
| Q4 2022 | Mar 30, 2023 · Before open |
| Q3 2022 | Nov 9, 2022 · Before open |
| Q2 2022 | Aug 11, 2022 · Before open |
All 16 quarters
| Quarter | Results |
|---|---|
| Q1 2022 | May 11, 2022 · Before open |
| Q4 2021 | Mar 31, 2022 · Before open |
| Q3 2021 | Nov 15, 2021 · Before open |
| Q2 2021 | Aug 12, 2021 · Before open |
| Q1 2021 | May 6, 2021 · Before open |
| Q4 2020 | Mar 9, 2021 · Before open |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (March 2025) | Investor deck | 36 slides | March 2025 |
| Investor Presentation (April 2024) | Investor deck | 32 slides | Apr 1, 2024 |
| Investor Presentation (January 2024) | Investor deck | 31 slides | January 2024 |
| Corporate Update (November 2023) | Corporate update | 34 slides | Nov 14, 2023 |
| Investor Presentation (October 2023) | Investor deck | 30 slides | October 2023 |
| Investor Presentation (September 2023) | Investor deck | 31 slides | Sep 6, 2023 |
| Investor Presentation (September 2023) | Investor deck | 31 slides | September 2023 |
| Investor Presentation (May 2023) | Investor deck | 39 slides | May 15, 2023 |
| Investor Presentation (March 2023) | Investor deck | 55 slides | Mar 30, 2023 |
| Investor Presentation (January 2023) | Investor deck | 52 slides | Jan 9, 2023 |
All 25 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (January 2023) | Investor deck | 22 slides | Jan 9, 2023 |
| Investor Presentation (November 2022) | Investor deck | 51 slides | Nov 9, 2022 |
| Investor Presentation (July 2022) | Investor deck | 46 slides | Jul 28, 2022 |
| Investor Presentation (April 2022) | Investor deck | 52 slides | Apr 20, 2022 |
| Corporate Update (March 2022) | Corporate update | 51 slides | Mar 31, 2022 |
| Investor Presentation (June 2021) | Investor deck | 50 slides | Jun 16, 2021 |
| Investor Presentation (May 2021) | Investor deck | 50 slides | May 6, 2021 |
| Investor Presentation (April 2021) | Investor deck | 50 slides | Apr 21, 2021 |
| Investor Presentation (March 2021) | Investor deck | 49 slides | Mar 9, 2021 |
| Investor Presentation (November 2020) | Investor deck | 41 slides | Nov 2, 2020 |
| Q2 2020 Earnings Presentation | Earnings | 41 slides | Aug 10, 2020 |
| Investor Presentation (June 2020) | Investor deck | 41 slides | Jun 2, 2020 |
| Investor Presentation (May 2020) | Investor deck | 40 slides | May 18, 2020 |
| Investor Presentation (April 2019) | Investor deck | 43 slides | April 2019 |
| Corporate Update (May 2016) | Corporate update | 16 slides | May 2, 2016 |
Financials
Annual, in USD
Income statement
| Line | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.13M | -418.0K | 567.0K | 3.07M | 31.0K | 5.73M | 0 | 3.75M | 6.25M | 0 |
| Cost of revenue | 1.67M | 3.02M | 954.0K | 182.0K | 108.0K | 0 | 490.0K | 90.0M | 44.1M | 40.5M |
| Gross profit | 1.46M | -3.44M | -387.0K | 2.89M | -77.0K | 5.73M | -490.0K | 3.75M | 6.25M | -40.5M |
| Research and development | 16.3M | 18.2M | 13.4M | 13.1M | 13.3M | 15.8M | 49.0M | 90.0M | 44.1M | 40.5M |
| Selling, general and administrative | 21.5M | 34.7M | 38.1M | 19.2M | 13.2M | 19.0M | 19.6M | 16.1M | 12.8M | 9.40M |
| Operating income | -35.3M | -56.4M | -51.9M | -29.5M | -26.6M | -30.5M | -70.4M | -102.3M | -50.6M | -49.9M |
| Depreciation and amortization | 334.0K | 382.0K | 428.0K | 477.0K | 562.0K | 645.0K | 490.0K | 246.0K | 207.9K | 239.4K |
| EBITDA | -35.0M | -56.0M | -51.5M | -29.0M | -26.0M | -29.9M | -69.9M | -102.0M | -50.4M | -49.7M |
| Interest expense | 3.64M | 1.26M | 1.00K | 29.0K | 931.0K | 2.23M | 2.78M | 1.74M | 334.4K | 70.7K |
| Income before tax | -40.0M | -53.7M | -51.6M | -29.1M | -24.9M | -30.0M | -71.9M | -103.0M | -50.5M | -49.7M |
| Income tax | 318.0K | -2.71K | -428.0K | 300.0K | 3.19M | 745.0K | 3.39M | -246.0K | -207.9K | 254.7K |
| Net income | -40.3M | -53.7M | -51.2M | -29.4M | -24.9M | -30.8M | -71.9M | -103.0M | -50.5M | -49.7M |
| Earnings per share, basic | -2.84 | -7.59 | -7.84 | -5.75 | -6.78 | -10.46 | -30.23 | -49.14 | -28.84 | -50.40 |
Balance sheet
| Line | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 33.0M | 38.3M | 66.9M | 109.4M | 32.3M | 32.9M | 16.6M | 24.3M | 46.8M | 36.2M |
| Short-term investments | 3.50M | 28.6M | 49.5M | 86.3M | 125.9M | 70.7M | ||||
| Receivables | 1 | 71.0K | 0 | |||||||
| Inventory | 0 | 906.0K | 2.35M | 1 | 0 | 0 | 0 | 0 | ||
| Current assets | 35.2M | 41.0M | 70.7M | 119.0M | 37.5M | 62.1M | 67.5M | 112.4M | 174.5M | 107.6M |
| Property, plant and equipment | 5.71M | 6.55M | 2.25M | 2.71M | 3.39M | 3.81M | 1.06M | 696.3K | 553.3K | |
| Goodwill | 0 | 0 | 0 | 0 | ||||||
| Total assets | 40.6M | 48.7M | 80.1M | 127.7M | 47.0M | 66.8M | 72.7M | 114.7M | 175.4M | 108.3M |
| Accounts payable | 2.30M | 2.37M | 4.55M | 1.69M | 1.05M | 1.42M | 1.42M | 8.75M | 6.75M | 4.34M |
| Current liabilities | 7.55M | 8.73M | 9.19M | 16.6M | 9.11M | 17.5M | 18.2M | 22.0M | 13.6M | 6.96M |
| Long-term debt | 30.8M | 13.4M | 4.81M | 15.7M | 13.3M | 18.2M | 1.79M | |||
| Total debt | 36.2M | 19.8M | 7.10M | 7.80M | 13.5M | 17.4M | 28.2M | 18.3M | 36.4M | 3.51M |
| Total liabilities | 48.3M | 33.1M | 15.5M | 23.7M | 16.9M | 25.3M | 38.1M | 36.1M | 32.2M | 9.13M |
| Shareholders' equity | -7.66M | 15.6M | 64.6M | 104.1M | 30.1M | 41.5M | 34.6M | 78.6M | 143.1M | 99.2M |
| Shares outstanding | 14.2M | 7.07M | 6.53M | 5.10M | 3.67M | 2.94M | 2.38M | 2.10M | 1.75M | 986.2K |
Cash flow
| Line | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -33.0M | -51.5M | -50.2M | -21.4M | -23.7M | -25.4M | -71.3M | -91.6M | -40.1M | -39.8M |
| Capital spending | -41.0K | -28.0K | -16.0K | -27.0K | -27.0K | -169.0K | -3.50M | -605.0K | -376.2K | -440.4K |
| Free cash flow | -33.1M | -51.5M | -50.2M | -21.4M | -23.7M | -25.5M | -74.8M | -92.2M | -40.5M | -40.2M |
| Cash from investing | -41.0K | 18.0K | -16.0K | 3.47M | 25.6M | 21.0M | 32.8M | 37.8M | -56.9M | -71.2M |
| Cash from financing | 26.3M | 23.5M | 7.73M | 95.0M | -2.50M | 20.6M | 31.0M | 32.3M | 107.6M | 109.2M |
| Dividends paid | -37.0K | -393.0K | -1.07M | -158.0K | 0 | 0 | 0 | 0 | ||
| Share buybacks | -2.00K | -37.0K | -393.0K | -1.07M | -158.0K | 33.3M | 21.1M | 32.3M | 91.2M | 107.4M |
| Change in cash | -6.76M | -28.0M | -42.5M | 77.1M | -581.0K | 16.2M | -7.49M | -21.4M | 10.6M | -1.76M |
Cap table
Built by 6ix from Trevena, Inc.’s releases
- Common shares
- 863,788
- Fully diluted
- 863,788
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 863,788 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 863,788 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Terrance McGuire Other companies: Tectonic Therapeutic, Inc. (Director · Since at least Jun 20, 2024); Invivyd, Inc. (Director · Since at least Aug 5, 2021); Seer, Inc. (Director · Since at least Dec 3, 2020); Cyclerion Therapeutics, Inc. (Director · Apr 1, 2019 – Nov 30, 2023 · Past); Alector, Inc. (Director · Feb 6, 2019 – Sep 11, 2023 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past); Pulmatrix, Inc. (Director · Jun 15, 2015 – May 16, 2019 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Mar 2, 2017 · Past); Ironwood Pharmaceuticals, Inc. (Director · Jun 3, 2013 – Apr 1, 2019 · Past) | Director · Jan 30, 2014 – May 14, 2014 · Past |
| François Nader Other companies: Tectonic Therapeutic, Inc. (Chair, Board of Directors · Since at least Feb 23, 2026); Moderna, Inc. (Director · Since at least Dec 10, 2019); Tourmaline Bio Inc. (Director · May 6, 2021 – Jun 13, 2023 · Past); Prevail Therapeutics Inc (Director · Jun 19, 2019 – Jan 22, 2021 · Past); Alexion Pharmaceuticals Inc (Director · Nov 15, 2017 – Jul 21, 2021 · Past); Baxalta Inc (Director · Jul 27, 2015 – Jun 3, 2016 · Past); Acceleron Pharma Inc (Director · Dec 11, 2014 – Nov 19, 2021 · Past); NPS Pharmaceuticals Inc (President, CEO and Director, Director · Apr 8, 2013 – Feb 21, 2015 · Past) | Director · Jan 30, 2014 – May 20, 2015 · Past |
| Maxine Gowen Other companies: Passage Bio, Inc. (Chairwoman · Since at least Feb 18, 2021); Aclaris Therapeutics, Inc. (Director · Since at least Jul 2, 2019); Aceragen Inc. (Director · Jan 4, 2015 – Aug 10, 2023 · Past); Akebia Therapeutics, Inc. (Director · Jul 28, 2014 – Jun 5, 2020 · Past); Human Genome Sciences Inc (Director · Feb 15, 2008 – Jul 30, 2012 · Past) | Director · Since at least Jan 30, 2014 |
| Anne Phillips Other companies: Sagimet Biosciences Inc. - Series A (Board Member · Since at least Aug 1, 2024); vTv Therapeutics Inc. (Director · Since at least Mar 13, 2024); Vaccitech plc (Director · Apr 29, 2021 – May 11, 2023 · Past); AMAG Pharmaceuticals Inc (Director · Apr 10, 2019 – Nov 16, 2020 · Past) | Member of Nominating and Corporate Governance Committee · Since at least Dec 16, 2014 |
| Farah Champsi Other companies: Population Health Investment Co Inc (Director · Nov 17, 2020 – Jan 26, 2021 · Past); Kite Pharma Inc (Director · Jun 19, 2014 – Oct 3, 2017 · Past); Portola Pharmaceuticals Inc (Director · May 21, 2013 – May 28, 2013 · Past); Chimerix Inc (Director · Apr 10, 2013 – Oct 23, 2013 · Past) | Director · Jan 30, 2014 – Dec 10, 2014 · Past |
| Julie McHugh Other companies: Lantheus Holdings, Inc. (Director · Since at least Jan 25, 2017); Ironwood Pharmaceuticals, Inc. (Chair, Biopharmaceutical Industry Executive, Retired · Since at least Jun 1, 2016); Evelo Biosciences, Inc. (Director · Apr 9, 2021 – Jun 8, 2023 · Past); Aerie Pharmaceuticals Inc. (Director · Jun 8, 2016 – Nov 21, 2022 · Past) | Chair of the Nominating and Corporate Governance Committee · Since at least May 18, 2016 |
| Leon O Moulder Jr Other companies: Zenas BioPharma, Inc. (See Remarks, Director · Since at least Sep 12, 2024); Zai Lab Ltd. (Director · Since at least Jan 1, 2021); Dianthus Therapeutics, Inc. (Director · Sep 11, 2023 – May 23, 2024 · Past); Tesaro Inc (Chief Executive Officer, Director · Mar 1, 2018 – Jan 22, 2019 · Past) | Director · May 16, 2018 – Jun 15, 2023 · Past |
| Jason Raleigh Nunn Other companies: Addex Therapeutics Ltd (Director · Since at least Mar 18, 2026); Zenas BioPharma, Inc. (Director · Since at least Sep 12, 2024); Regulus Therapeutics Inc (Director · Since at least Jun 6, 2019) | Director · May 16, 2019 – Jun 13, 2024 · Past |
| David F Solomon Other companies: Clinical Data Inc (Vice President, Director · Apr 13, 2011 – Apr 13, 2011 · Past); Forest Laboratories Inc (SVP-CorpDev/Strategic Planning · Dec 8, 2008 – Dec 6, 2013 · Past) | Director · Jan 30, 2014 – May 14, 2014 · Past |
| John P. Hamill Other companies: Aprea Therapeutics, Inc. (Senior Vice President and Chief Financial Officer · Since at least Jan 30, 2023); Windtree Therapeutics, Inc. (SVP & CFO · Jul 20, 2020 – Jul 26, 2022 · Past) | VP Fin,Princ Fin&Acct Officer · May 31, 2019 – May 31, 2019 · Past |
All 25 people
| Person | Seat |
|---|---|
| Barry Shin Other companies: Compass Therapeutics, Inc. (Chief Financial Officer · Since at least Dec 9, 2024) | Acting COO and CFO · Jun 25, 2019 – Oct 8, 2024 · Past |
| John M Limongelli Other companies: Neos Therapeutics Inc (SVP & General Counsel · Mar 20, 2019 – Mar 19, 2021 · Past) | Sr. VP,General Counsel & CAO · Feb 28, 2018 – Feb 28, 2018 · Past |
| Marvin Johnson Other companies: Marinus Pharmaceuticals Inc (Director · Apr 17, 2023 – Feb 7, 2025 · Past) | Director · Mar 18, 2021 – Jun 13, 2024 · Past |
| Barbara Yanni | Chair of Compensation Committee · Since at least Nov 5, 2026 |
| Carrie L. Bourdow | President and Chief Executive Officer · Since at least Nov 5, 2026 |
| Jake R. Nunn | Member of the Nominating and Corporate Governance Committee · Since at least Nov 5, 2026 |
| Katrine Sutton | VP, Finance · Nov 26, 2024 – Nov 26, 2024 · Past |
| Leon O. Moulder | Chairman of the Board · Since at least Nov 5, 2026 |
| Mark Demitrack | Acting CMO · Dec 2, 2023 – Oct 8, 2024 · Past |
| Michael R. Dougherty | Executive Chairman · Since at least Nov 5, 2026 |
| Patricia M Drake | SVP, Chief Commercial Officer · Nov 10, 2022 – Dec 14, 2023 · Past |
| Robert Prachar | Sr. VP, Corp. Strategy · Mar 31, 2014 – Mar 31, 2014 · Past |
| Robert Yoder | Senior Vice President and Chief Business Officer · Since at least Nov 5, 2026 |
| Scott Applebaum | Corporate Secretary · Since at least Nov 5, 2026 |
| Scott Braunstein | Operating Partner at Aisling Capital Management LP · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Trevena, Inc.